Literature DB >> 12873798

Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects.

Ronald M Salomon1, Beth Ripley, John S Kennedy, Benjamin Johnson, Dennis Schmidt, Jamie M Zeitzer, Seiji Nishino, Emmanuel Mignot.   

Abstract

BACKGROUND: Hypocretins, excitatory neuropeptides at monoaminergic synapses, appear to regulate human sleep-wake cycles. Undetectable cerebrospinal fluid hypocretin-1 levels are seen in narcolepsy, which is frequently associated with secondary depression. Shortened rapid eye movement latency is observed in both narcolepsy and depression. Cerebrospinal fluid hypocretin-1 levels have not been reported in mood disorders.
METHODS: We examined hypocretin-1 levels in 14 control and 15 depressed subjects. Cerebrospinal fluid was drawn continuously in supine subjects for 24 hours with an indwelling intrathecal catheter under entrained light-dark conditions. Depressed subjects were studied before and after 5 weeks of sertraline (n=10, three nonresponders) or bupropion (n=5, two nonresponders).
RESULTS: Hypocretin-1 levels varied slightly (amplitude 10%) but significantly across the diurnal cycle in control subjects, with amplitude significantly reduced in depression (3%). Levels were lowest at midday, surprising for a hypothetically wake-promoting peptide. Mean hypocretin levels trended higher in depressive than in control subjects. Hypocretin-1 levels decreased modestly but significantly after sertraline (-14%) but not bupropion.
CONCLUSIONS: Our results are consistent with previous physiologic findings in depression indicating dampened diurnal variations in hypocretin-1. The finding that sertraline but not bupropion slightly decreased cerebrospinal fluid hypocretin-1 indicates a serotoninergic influence on hypocretin tone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873798     DOI: 10.1016/s0006-3223(02)01740-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  72 in total

Review 1.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 2.  Mood-related central and peripheral clocks.

Authors:  Kyle D Ketchesin; Darius Becker-Krail; Colleen A McClung
Journal:  Eur J Neurosci       Date:  2018-11-29       Impact factor: 3.386

3.  Orexin/hypocretin in psychiatric disorders: present state of knowledge and future potential.

Authors:  Stephanie L Borgland; Gwenaël Labouèbe
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 4.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 5.  Circadian rhythms and sleep--the metabolic connection.

Authors:  Urs Albrecht
Journal:  Pflugers Arch       Date:  2011-06-28       Impact factor: 3.657

6.  Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency.

Authors:  S P Deats; W Adidharma; J S Lonstein; L Yan
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

Review 7.  Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation.

Authors:  Kevin G Burfeind; Vijayshree Yadav; Daniel L Marks
Journal:  Curr Neurol Neurosci Rep       Date:  2016-11       Impact factor: 5.081

8.  The effect of clomipramine on wake/sleep and orexinergic expression in rats.

Authors:  P Feng; Y Hu; D Li; D Vurbic; H Fan; S Wang; K P Strohl
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

9.  Locomotor-dependent and -independent components to hypocretin-1 (orexin A) regulation in sleep-wake consolidating monkeys.

Authors:  Jamie M Zeitzer; Christine L Buckmaster; David M Lyons; Emmanuel Mignot
Journal:  J Physiol       Date:  2004-04-23       Impact factor: 5.182

10.  A key role for orexin in panic anxiety.

Authors:  Philip L Johnson; William Truitt; Stephanie D Fitz; Pamela E Minick; Amy Dietrich; Sonal Sanghani; Lil Träskman-Bendz; Andrew W Goddard; Lena Brundin; Anantha Shekhar
Journal:  Nat Med       Date:  2009-12-27       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.